Diabetes News Hound

The Food and Drug Administration has approved a new Type 2 diabetes Drug. It’s called Tradjenta and is being jointly marketed by Boehringer Ingelheim and Eli Lilly (more…)

Becton Dickinson said that it is developing technology that can deliver insulin in tandem with the artificial pancreas more efficiently (more…)

U.S. regulators have rejected Afrezza, a new, supposedly more effective version of inhalable rapid-acting insulin (more…)

University of Kansas researchers say they have developed a drug called KU-32 that can prevent some of the more severe complications of diabetes in mice, including amputations of extremities (more…)

The FDA surprised many on Wednesday when it declined to approve Amylin Pharmaceuticals’s once-a-week Type 2 diabetes drug Bydureon (more…)

Drugmaker Sanofi-Aventis said recently that it will announce “at least another couple” key diabetes-related partnerships in the coming months (more…)

Regulators are examining whether there is a link between Type 2 diabetes drug Actos and bladder cancer (more…)

Bristol-Myers Squibb and AstraZeneca recently said that their experimental once-a-day drug dapagliflozin, currently in clinical trials, has proven more effective at lowering blood sugar levels than an older medication (more…)

AstraZeneca and University College London have formed a research partnership to develop treatments for diabetic retinopathy, or eyesight damage afflicting diabetics (more…)